SCHEMBL831372

SCHEMBL831372

CC(C)C(=O)CC(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
MAPK1 P28482 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
SLC15A1 P46059 2/20 0.52
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ATM Q13315 1/20 0.48
CDC25B P30305 1/20 0.48
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
MMP9 P14780 1/20 0.46
TSHR P16473 1/20 0.46
CTSK P43235 2/20 0.46
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28132760 0.90 ALDH1A1 (0.49) ALDH1A1MAPK1L3MBTL1SLC15A1SLC6A2
SCHEMBL8279036 0.85 ALDH1A1 (0.56) ALDH1A1MAPK1L3MBTL1SLC15A1SLC6A2
SCHEMBL28319473 0.85 SMN1; SMN2 (0.46) ALDH1A1MAPK1L3MBTL1SLC15A1TDP1
SCHEMBL7667014 0.83 ALDH1A1 (0.54) ALDH1A1MAPK1L3MBTL1SLC15A1SLC6A2
SCHEMBL1268516 0.83 ALDH1A1 (0.51) ALDH1A1MAPK1L3MBTL1SLC15A1SLC6A2
SCHEMBL294341 0.83 ALDH1A1 (0.73) ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3
SCHEMBL9364881 0.83 ALDH1A1 (0.50) ALDH1A1MAPK1L3MBTL1SLC15A1ATM
SCHEMBL14864158 0.83 ALDH1A1 (0.50) ALDH1A1MAPK1L3MBTL1SLC15A1SLC6A2
SCHEMBL17048768 0.83 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1SLC15A1SLC6A2
SCHEMBL3975330 0.82 ALDH1A1 (0.56) ALDH1A1MAPK1L3MBTL1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209612-A1 PROCESS FOR THE PREPARATION OF ATORVASTATIN RANBAXY LABORATORIES LIMITED (IN) 2009-08-20 US claimed
EP-1756053-A1 PROCESS FOR THE PREPARATION OF ATORVASTATIN Ranbaxy Laboratories Limited (IN) 2007-02-28 EP claimed
WO-2005118536-A1 PROCESS FOR THE PREPARATION OF ATORVASTATIN RANBAXY LABORATORIES LIMITED (IN) 2005-12-15 WO claimed
US-12565595-B2 Aqueous coating material composition and method for forming multilayer coating film KANSAI PAINT CO., LTD. (JP) 2026-03-03 US disclosed
US-20250346779-A1 Method of Forming A Coating Film KANSAI PAINT CO LTD (JP) 2025-11-13 US disclosed
US-20250340751-A1 Automobile Body Coating Method KANSAI PAINT CO LTD (JP) 2025-11-06 US disclosed
US-20250154374-A1 AQUEOUS COATING MATERIAL COMPOSITION AND METHOD FOR FORMING MULTILAYER COATING FILM KANSAI PAINT CO., LTD. (JP) 2025-05-15 US disclosed
EP-4481010-A1 AQUEOUS COATING MATERIAL COMPOSITION AND METHOD FOR FORMING MULTILAYER COATING FILM Kansai Paint Co., Ltd. (JP) 2024-12-25 EP disclosed
CN-116829662-B Aqueous coating composition and method for forming multilayer coating film 关西涂料株式会社 2024-10-29 CN disclosed
EP-3689476-B1 METHOD FOR FORMING MULTILAYER COATING FILM KANSAI PAINT CO LTD (JP) 2024-10-02 EP disclosed
US-20240309239-A1 AQUEOUS COATING MATERIAL COMPOSITION AND METHOD FOR FORMING MULTILAYER COATING FILM KANSAI PAINT CO., LTD. (JP) 2024-09-19 US disclosed
US-20090209693-A1 Silver Beta-Ketocarboxylate, Material Comprising the Same for Forming Silver Metal, and Use Thereof OSAKA INDUSTRIAL PROMOTION (JP) 2009-08-20 US disclosed
US-20090209612-A1 PROCESS FOR THE PREPARATION OF ATORVASTATIN RANBAXY LABORATORIES LIMITED (IN) 2009-08-20 US disclosed
US-20090209612-A1 PROCESS FOR THE PREPARATION OF ATORVASTATIN RANBAXY LABORATORIES LIMITED (IN) 2009-08-20 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed
EP-1905756-A1 SILVER BETA-KETOCARBOXYLATE, MATERIAL COMPRISING THE SAME FOR FORMING SILVER METAL, AND USE THEREOF OSAKA UNIVERSITY (JP) 2008-04-02 EP disclosed
EP-1756053-A1 PROCESS FOR THE PREPARATION OF ATORVASTATIN Ranbaxy Laboratories Limited (IN) 2007-02-28 EP disclosed
WO-2006110918-A1 PYRROLE COMPOUNDS AND USES THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2006-10-19 WO disclosed
WO-2005118536-A1 PROCESS FOR THE PREPARATION OF ATORVASTATIN RANBAXY LABORATORIES LIMITED (IN) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12565595-B2 Aqueous coating material composition and method for forming multilayer coating film DRD2, CHRM1, PNMT ALDH1A1 2369/4885MAPK1 1131/4885L3MBTL1 3045/4885
US-20090209693-A1 Silver Beta-Ketocarboxylate, Material Comprising the Same for Forming Silver Metal, and Use Thereof PCCA, BCKDK, MCCC2 ALDH1A1 105/4885MAPK1 3827/4885L3MBTL1 2772/4885
US-20090209612-A1 PROCESS FOR THE PREPARATION OF ATORVASTATIN HMGCR, DHCR7, LDLR ALDH1A1 2416/4885MAPK1 1571/4885L3MBTL1 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.